M. Green

发表

Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

G. Mills, G. Hortobagyi, L. Pusztai, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer

G. Hortobagyi, V. Valero, N. Ibrahim, 2015 .

Monoclonal antibody therapy for solid tumors.

J. Murray, G. Hortobagyi, G N Hortobagyi, 2000, Cancer treatment reviews.

Single session whole body T 2-weighted and T 1-weighted MRI ( both with and without fat suppression )

G. Hortobagyi, J. Ma, V. Kundra, 2007 .

A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy.

G. Hortobagyi, L. Pusztai, H. Kuerer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

G. Mills, G. Hortobagyi, L. Pusztai, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival among women with triple receptor-negative breast cancer and brain metastases.

F. Esteva, A. González-Angulo, Marjorie C. Green, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Repeated femoral vein cannulation for administration of chemotherapeutic agents.

F. Muggia, J. Speyer, M. Levin, 1983, Cancer treatment reports.

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients

V. Valero, R. Theriault, J. Murray, 2010, British Journal of Cancer.

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

G. Hortobagyi, L. Pusztai, V. Valero, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

G. Hortobagyi, L. Pusztai, H. Kuerer, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

G. Hortobagyi, V. Valero, N. Ibrahim, 2015, Clinical breast cancer.